changes in the classification of dlbcl
Published 4 years ago • 111 plays • Length 7:16Download video MP4
Download video MP3
Similar videos
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:28
how the standard of care for dlbcl is changing with the introduction of novel agents
-
1:34
advances and unmet needs in second-line treatment of dlbcl
-
1:33
the difficulties of mrd detection in dlbcl
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
6:24
indiko biochemistry analyzer demonstration
-
8:21
blc datacheck sn
-
7:11
lymphoma dlbcl coping with chemo
-
3:04
applying molecular understanding of dlbcl to management strategies
-
1:09
interim analysis of anbal-cel for r/r dlbcl
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
1:06
an ongoing phase i trial evaluating as-1763, a novel non-covalent btki, in b-cell lymphomas
-
3:22
the latest data in diffuse large b-cell lymphoma from icml 2017
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:53
autohct in dlbcl in the car-t era
-
2:44
data on new therapeutic strategies in hodgkin lymphoma
-
1:01
recent and future changes in the landscape of aml: the addition of venetoclax and mrd eradication
-
2:41
an overview of the latest advances in hematology
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
0:45
difference between quality of life & patient-reported outcomes
-
1:45
the importance of real-world data in cll & efficacy of btk and bcl-2 inhibitors in the real world
-
3:21
safety management of car-t cell therapy in dlbcl